Stanley Penc, MD
Neurology · Albany, NYNPI 1003078031
Payments from drug & device makers
Across 1,049 payments — averaging $626.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- EMD Serono, Inc.$223K
- Biogen$202K
- Amgen$98K
- TG Therapeutics, Inc.$70K
- AbbVie$22K
- Axsome Therapeutics, Inc.$13K
- plus $30K from 20 others
What the payments were for
- Consulting fees$48,2797%
- Speaking & faculty fees$540,12082%
- Travel & lodging$42,0066%
- Food & beverage$26,8564%
- Education$1670%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| EMD Serono, Inc. | 235 | $222,603 |
| Biogen | 191 | $202,120 |
| Amgen(2 entities) | 156 | $98,153 |
| TG Therapeutics, Inc. | 47 | $70,273 |
| AbbVie(2 entities) | 151 | $22,075 |
| Axsome Therapeutics, Inc. | 6 | $12,508 |
| Genentech USA, Inc. | 6 | $9,076 |
| Novartis | 124 | $7,395 |
| Pfizer | 47 | $5,241 |
| E.r. Squibb & Sons, L.L.C. | 5 | $3,153 |
| Bristol Myers Squibb | 27 | $1,386 |
| Genentech, Inc. | 1 | $1,260 |
| Sanofi | 13 | $541 |
| Lilly USA, LLC | 4 | $347 |
| Argenx US, Inc. | 4 | $312 |
| MDD US Operations, LLC | 4 | $209 |
| Biohaven Pharmaceuticals, Inc. | 9 | $177 |
| Eisai Inc. | 2 | $153 |
| Livanova USA, Inc. | 4 | $145 |
| Lundbeck LLC | 5 | $123 |
| Abbott | 2 | $69 |
| Jazz Pharmaceuticals Inc. | 1 | $38 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $31 |
| SK Life Science, Inc. | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $14 |
| Johnson & Johnson | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$657,428 in reported general payments places this provider in the 95th percentile of 1,623 neurology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 36 | $473,384 |
| Kesimpta PenOfatumumab | 33 | $296,687 |
| GammaplexImmun Glob G(Igg)/Gly/Iga 0-50 | 16 | $244,183 |
| VumerityDiroximel Fumarate | 22 | $225,333 |
| Avonex (4 Pack)Interferon Beta-1a | 23 | $194,608 |
| GammakedImmune Globul G/Gly/Iga Avg 46 | 12 | $184,744 |
| AubagioTeriflunomide | 20 | $183,476 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 13 | $173,273 |
| CopaxoneGlatiramer Acetate | 28 | $160,022 |
| Nurtec OdtRimegepant Sulfate | 81 | $139,484 |
| TecfideraDimethyl Fumarate | 17 | $129,514 |
| Dalfampridine ErDalfampridine | 73 | $114,521 |
| Teriflunomide | 65 | $100,749 |
| Dimethyl Fumarate | 34 | $76,999 |
| QuliptaAtogepant | 57 | $62,149 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BiogenVumerity, Avonex (4 Pack), Tecfidera | $202,120 | $549,45562 claims |
| SanofiAubagio | $541 | $183,47620 claims |
| PfizerNurtec Odt, Lyrica, Dilantin | $5,241 | $154,023110 claims |
| AbbVieQulipta, Ubrelvy | $22,075 | $109,398101 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,623 neurology providers in New York.
Other neurology in Albany
- Richard HolubAlbany$6.3M
- Krupa PandeyAlbany$3.8M
- Charles ArgoffAlbany$1.7M
- David HartAlbany$1.7M
- Christian GrommesNew York$9.9M
- Ilya KisterNew York$9.5M
- E DorseyNew York$8.5M
- Lauren SchaffNew York$8.2M
- Martin SadowskiNew York$5.4M
- Lawrence HonigNew York$4.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.